MAGIC in practice: Experience of peri‐operative ECF/X chemotherapy in gastro‐esophageal adenocarcinomas

Alexander M. Reece-Smith(Nottingham University Hospitals NHS Trust), Simon L. Parsons(Galapagos (Belgium)), Swati Saha(University of Delhi), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), K Hameed(Nottingham University Hospitals NHS Trust), John P. Duffy(Nottingham University Hospitals NHS Trust), E.M. Bessell(University Hospitals Birmingham NHS Foundation Trust), M. Cunnell(Nottingham University Hospitals NHS Trust)

Journal of Surgical Oncology

June 4, 2012

10.1002/jso.23187

Cited by 20

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

|New England Journal of Medicine|2010|4.5k

Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial

|The Lancet|2009|1.5k

Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial

|The Lancet|2009|1.1k

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

|The Lancet|2022|664

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

|The Lancet Oncology|2013|605